10x Genomics rises on bladder cancer diagnostics partnership with Cleveland Clinic
BUZZ-10x Genomics rises on bladder cancer diagnostics partnership with Cleveland Clinic ** Shares of biotech firm 10x Genomics TXG.O rise 2.7% to $32.59
** Co says it is partnering with Cleveland Clinic to develop diagnostic tools for bladder cancer, a disease affecting the cells lining the bladder
** Says study will identify markers to predict patient response to antibody-drug conjugates and immunotherapies, treatments that target cancer cells or boost immune response
** Says researchers will analyze tumor samples using gene and protein profiling at single-cell level
** Project will study how tumors and surrounding environment respond to treatment, to identify resistance factors
** Says dataset could enable more personalized treatment decisions and new diagnostic test development
** Including sessions's move, stock up ~99% YTD
(Reporting by Sahil Pandey in Bengaluru)
Recent news on 10x Genomics
See all newsBrief: 10X Genomics Announces New Collaboration To Advance Single Cell And Spatial Applications Across Solid Tumors And Blood Cancers
U.S. RESEARCH ROUNDUP-Autodesk, Hubspot, Oracle
Delaware jury finds Parse infringed three genetic-sequencing patents (updated)
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
Brief: 10X Genomics Wins Patent Infringement Verdict Against Parse Biosciences